Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 6.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 185,220 shares of the life sciences company’s stock after buying an additional 10,568 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Illumina were worth $24,751,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Sterling Capital Management LLC lifted its holdings in Illumina by 20.9% in the fourth quarter. Sterling Capital Management LLC now owns 17,118 shares of the life sciences company’s stock valued at $2,287,000 after acquiring an additional 2,960 shares during the period. Neuberger Berman Group LLC increased its holdings in shares of Illumina by 2.5% in the 4th quarter. Neuberger Berman Group LLC now owns 147,194 shares of the life sciences company’s stock valued at $19,670,000 after purchasing an additional 3,571 shares in the last quarter. Scotia Capital Inc. lifted its stake in shares of Illumina by 30.1% in the fourth quarter. Scotia Capital Inc. now owns 16,315 shares of the life sciences company’s stock valued at $2,180,000 after purchasing an additional 3,771 shares during the period. Bessemer Group Inc. boosted its holdings in Illumina by 32,837.5% during the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company’s stock worth $180,152,000 after buying an additional 1,344,038 shares in the last quarter. Finally, DRW Securities LLC acquired a new position in Illumina during the fourth quarter worth about $201,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on ILMN. Stephens reissued an “overweight” rating and set a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Royal Bank of Canada dropped their price target on Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a research report on Tuesday, April 8th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a research report on Friday, February 28th. Finally, Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and a consensus target price of $138.70.

Illumina Stock Performance

Illumina stock opened at $74.78 on Monday. The stock has a fifty day moving average price of $88.58 and a 200 day moving average price of $122.25. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The firm has a market capitalization of $11.85 billion, a P/E ratio of -9.74, a PEG ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.